The Short Answer
Semaglutide, Ozempic, and Wegovy are all the same molecule — semaglutide — but formulated differently and approved for different indications. Ozempic is injectable semaglutide approved for type 2 diabetes management. Wegovy is injectable semaglutide approved for chronic weight management. Rybelsus is oral semaglutide approved for type 2 diabetes. The active pharmaceutical ingredient in all three is identical: semaglutide. The differences lie in dose, delivery system, approval indication, and brand. Research-grade semaglutide is the same molecule sold under Research-Use-Only (RUO) designation for laboratory investigation of GLP-1 receptor biology.
What Is Semaglutide?
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a peptide engineered to mimic and extend the biological activity of the endogenous incretin hormone GLP-1. It was developed by Novo Nordisk and first approved by the FDA in 2017 (Ozempic, for type 2 diabetes). With a molecular weight of approximately 4,114 Da, semaglutide is a 31-amino acid GLP-1 analogue modified with a C18 fatty diacid side chain via a hydrophilic linker — enabling albumin binding and a plasma half-life of approximately 7 days, supporting once-weekly dosing. For a comprehensive overview of semaglutide’s mechanism and research applications, see our Semaglutide Research Overview.
Ozempic, Wegovy, and Rybelsus: The Same Molecule, Different Applications
Ozempic (Injectable Semaglutide — Diabetes Indication)
Ozempic is subcutaneous injectable semaglutide approved by the FDA in December 2017 for glycemic control in adults with type 2 diabetes, and to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Ozempic is available in 0.5mg, 1mg, and 2mg weekly doses. It is not FDA-approved for weight management — though significant weight loss is observed as a side effect and is one reason for the compound’s enormous off-label interest.
Wegovy (Injectable Semaglutide — Weight Management Indication)
Wegovy is subcutaneous injectable semaglutide approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Wegovy uses a higher maintenance dose than Ozempic — 2.4mg weekly — following a titration schedule. The molecule is identical to Ozempic; the different brand name, dose, and indication reflect a separate regulatory approval pathway. Wegovy received an additional FDA approval in 2024 for cardiovascular risk reduction in adults with obesity and established cardiovascular disease.
Rybelsus (Oral Semaglutide — Diabetes Indication)
Rybelsus is oral semaglutide — the first oral GLP-1 receptor agonist approved by the FDA (2019), for glycemic control in adults with type 2 diabetes. Oral delivery of a peptide the size of semaglutide required a novel formulation technology — co-formulation with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC), an absorption enhancer that facilitates gastric absorption of the peptide before it reaches the proteolytic environment of the small intestine. Oral bioavailability with this system is approximately 1% compared to subcutaneous injection, requiring much higher oral doses (7mg, 14mg) to achieve comparable plasma exposures to injectable semaglutide.
Research-Grade Semaglutide vs Branded Products
Same Molecule, Different Regulatory Status
Research-grade semaglutide sold under RUO designation is chemically identical to the active pharmaceutical ingredient in Ozempic, Wegovy, and Rybelsus — the same 31-amino acid sequence with the same C18 fatty diacid modification. The difference is regulatory status and intended use. FDA-approved semaglutide products have completed the full clinical trial and manufacturing quality review required for human therapeutic use. Research-grade semaglutide is a laboratory reagent sold for in vitro and preclinical research investigation of GLP-1 receptor biology — not for human administration.
Why Researchers Use Research-Grade Semaglutide
Research-grade GLP-1 receptor agonists are essential tools for investigating the mechanistic biology of the GLP-1 receptor pathway — studying receptor pharmacology, downstream signaling cascades, metabolic effects in cell and animal models, combination protocols with other metabolic compounds, and comparative receptor studies alongside Tirzepatide and Retatrutide. The research literature on semaglutide is extensive and continues to grow across metabolic disease, cardiovascular biology, neurological function, and beyond. For the full mechanistic research landscape, see our Semaglutide Research Overview and Tirzepatide vs Semaglutide comparison.
The GLP-1 Research Landscape: Beyond Semaglutide
Semaglutide is a GLP-1 monoagonist — the reference standard for GLP-1 receptor-specific research. Understanding the broader GLP-1 axis research landscape helps contextualize where semaglutide fits among the newer generation of multi-receptor agonists:
- Semaglutide — GLP-1R monoagonist. Reference standard for GLP-1 pathway research. Available at AminoForge.
- Tirzepatide — GLP-1R + GIPR dual agonist. Adds GIP receptor biology. FDA-approved as Mounjaro and Zepbound. Available at AminoForge.
- Retatrutide — GLP-1R + GIPR + GCGR triagonist. Adds glucagon receptor for thermogenesis research. Available at AminoForge.
- Cagrilintide — Amylin receptor agonist. Complementary pathway to GLP-1 for combination metabolic research. Available at AminoForge.
For a systematic comparison of these compounds for research design selection, see our Tirzepatide Research Overview and Retatrutide Research Overview. For further reading on semaglutide’s mechanism see: Semaglutide GLP-1 receptor agonism and metabolic effects (PubMed).
Shop Semaglutide at AminoForge — ≥99% purity, COA verified, USA manufactured, ships within 48 hours.
All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.